Company Filing History:
Years Active: 2011
Title: Silvo Zuppancic: Innovating in Pharmaceutical Chemistry
Introduction
Silvo Zuppancic is a notable inventor based in Novo Mesto, Slovenia. His contributions to the field of pharmaceutical chemistry are exemplified by his work on sartan derivatives. With a focus on innovative processes, Silvo has made significant strides in the development of intermediates that have potential applications in medicine.
Latest Patents
Silvo Zuppancic holds one patent titled "Process for the preparation of sartan derivatives and intermediates useful in such process." This invention outlines a detailed method for the synthesis of a sartan derivative, which includes reacting 2-cyanophenylboronic acid or its derivatives with a p-halobenzyl-1H-imidazole derivative in the presence of a transition metal catalyst and a base. The patent not only addresses the end products but also identifies new intermediates, emphasizing the depth of Silvo's research.
Career Highlights
Silvo is employed at Krka, d.d., a prominent pharmaceutical company in Novo Mesto. His role at Krka involves applying his expertise in pharmaceutical chemistry to develop innovative solutions that contribute to medical advancements. His work has positioned him as a key figure within the pharmaceutical research community.
Collaborations
Throughout his career, Silvo has collaborated with several esteemed colleagues, including Miroslav Veverka and Martin Putala. These partnerships underscore the collaborative spirit of innovation at Krka, where interdisciplinary teamwork is vital for enhancing research outcomes and fostering new ideas.
Conclusion
Silvo Zuppancic's contributions through his patent in sartan derivatives highlight the importance of innovative processes in pharmaceutical development. His work at Krka and collaborations with fellow researchers reflect a commitment to advancing healthcare through scientific innovation. As the pharmaceutical landscape continues to evolve, inventors like Silvo play a crucial role in driving the industry forward.